Literature DB >> 21224072

Proteasome inhibitors induce p53-independent apoptosis in human cancer cells.

Bulbul Pandit1, Andrei L Gartel.   

Abstract

Proteasome inhibitors are used against human cancer, but their mechanisms of action are not entirely understood. For example, the role of the tumor suppressor p53 is controversial. We reevaluated the role of p53 in proteasome inhibitor-induced apoptosis by using isogenic human cancer cell lines with different p53 status. We found that well-known proteasome inhibitors such as MG132 and bortezomib, as well as the recently discovered proteasome inhibitor thiostrepton, induced p53-independent apoptosis in human cancer cell lines that correlated with p53-independent induction of proapoptotic Noxa but not Puma protein. In addition, these drugs inhibited growth of several cancer cell lines independently of p53 status. Notably, thiostrepton induced more potent apoptosis in HepG2 cells with p53 knockdown than in parental cells with wild-type p53. Our data confirm that proteasome inhibitors generally induce p53-independent apoptosis in human cancer cells. Copyright Â
© 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21224072      PMCID: PMC3069903          DOI: 10.1016/j.ajpath.2010.11.010

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  32 in total

1.  Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria.

Authors:  S G Kennedy; E S Kandel; T K Cross; N Hay
Journal:  Mol Cell Biol       Date:  1999-08       Impact factor: 4.272

2.  p53 has a direct apoptogenic role at the mitochondria.

Authors:  Motohiro Mihara; Susan Erster; Alexander Zaika; Oleksi Petrenko; Thomas Chittenden; Petr Pancoska; Ute M Moll
Journal:  Mol Cell       Date:  2003-03       Impact factor: 17.970

3.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage.

Authors:  F Bunz; A Dutriaux; C Lengauer; T Waldman; S Zhou; J P Brown; J M Sedivy; K W Kinzler; B Vogelstein
Journal:  Science       Date:  1998-11-20       Impact factor: 47.728

4.  p53-dependent induction of apoptosis by proteasome inhibitors.

Authors:  U G Lopes; P Erhardt; R Yao; G M Cooper
Journal:  J Biol Chem       Date:  1997-05-16       Impact factor: 5.157

Review 5.  The role of the cyclin-dependent kinase inhibitor p21 in apoptosis.

Authors:  Andrei L Gartel; Angela L Tyner
Journal:  Mol Cancer Ther       Date:  2002-06       Impact factor: 6.261

Review 6.  Proteolysis. The proteasome: a protein-degrading organelle?

Authors:  D M Rubin; D Finley
Journal:  Curr Biol       Date:  1995-08-01       Impact factor: 10.834

7.  Disruption of p53 in human cancer cells alters the responses to therapeutic agents.

Authors:  F Bunz; P M Hwang; C Torrance; T Waldman; Y Zhang; L Dillehay; J Williams; C Lengauer; K W Kinzler; B Vogelstein
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

8.  The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells.

Authors:  X-Y Pei; Y Dai; S Grant
Journal:  Leukemia       Date:  2003-10       Impact factor: 11.528

Review 9.  Clinical update: proteasome inhibitors in solid tumors.

Authors:  Heinz Josef Lenz
Journal:  Cancer Treat Rev       Date:  2003-05       Impact factor: 12.111

10.  Molecular sequelae of proteasome inhibition in human multiple myeloma cells.

Authors:  Nicholas Mitsiades; Constantine S Mitsiades; Vassiliki Poulaki; Dharminder Chauhan; Galinos Fanourakis; Xuesong Gu; Charles Bailey; Marie Joseph; Towia A Libermann; Steven P Treon; Nikhil C Munshi; Paul G Richardson; Teru Hideshima; Kenneth C Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

View more
  30 in total

1.  Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma.

Authors:  Sachiko Ohshima-Hosoyama; Monika A Davare; Tohru Hosoyama; Laura D Nelon; Charles Keller
Journal:  J Neurooncol       Date:  2011-06-03       Impact factor: 4.130

2.  Proteasomes regulate hepatitis B virus replication by degradation of viral core-related proteins in a two-step manner.

Authors:  Zi-Hua Zheng; Hui-Ying Yang; Lin Gu; Xiao-Mou Peng
Journal:  Virus Genes       Date:  2016-04-22       Impact factor: 2.332

Review 3.  Proteasome dysfunction in cardiomyopathies.

Authors:  Jennifer E Gilda; Aldrin V Gomes
Journal:  J Physiol       Date:  2017-03-16       Impact factor: 5.182

4.  The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib.

Authors:  Azmi Yerlikaya; Emrah Okur; Engin Ulukaya
Journal:  Tumour Biol       Date:  2012-04-04

5.  Senescence associated secretory phenotype profile from primary lung mice fibroblasts depends on the senescence induction stimuli.

Authors:  L A Maciel-Barón; S L Morales-Rosales; A A Aquino-Cruz; F Triana-Martínez; S Galván-Arzate; A Luna-López; V Y González-Puertos; N E López-Díazguerrero; C Torres; Mina Königsberg
Journal:  Age (Dordr)       Date:  2016-02-11

6.  Targeted ovarian cancer treatment: the TRAILs of resistance.

Authors:  Nadzeya Goncharenko Khaider; Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  Am J Cancer Res       Date:  2011-11-21       Impact factor: 6.166

7.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

8.  Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing.

Authors:  Claire L Soave; Tracey Guerin; Jinbao Liu; Q Ping Dou
Journal:  Cancer Metastasis Rev       Date:  2017-12       Impact factor: 9.264

9.  A preclinical evaluation of thiostrepton, a natural antibiotic, in nasopharyngeal carcinoma.

Authors:  Yen-Bin Hsu; Ming-Chin Lan; Yu-Lun Kuo; Chi-Ying F Huang; Ming-Ying Lan
Journal:  Invest New Drugs       Date:  2019-04-16       Impact factor: 3.850

10.  Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.

Authors:  Shruti Bhatt; Brittany M Ashlock; Ngoc L Toomey; Luis A Diaz; Enrique A Mesri; Izidore S Lossos; Juan Carlos Ramos
Journal:  J Clin Invest       Date:  2013-05-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.